The Next Phase: FDA Looks Beyond Three-Stage Drug Development Model

The move towards mechanism-based therapies may call for clinical development programs that diverge from the traditional three-phase regime, FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said